Misconceptions Remain on Gene Signature Use in Breast Cancer

Most specialists reached a consensus, although some may require more education on the clinical utility of breast cancer multigene signatures in early-stage disease, experts say.

Related Keywords

Italy , Milan , Lombardia , Berlin , Germany , Giuseppe Curigliano , Division Of Early Drug Development , University Of Milan , European Institute Of Oncology , European Society For Medical Oncology , Breast Cancer Congress , Early Drug Development , European Institute , European Society , Medical Oncology , Breast Cancer , Alignant Breast Neoplasm , Cancer , Alignant Neoplasia , Arcinoma , Breast , Chemotherapy , Endocrine Therapy , Her2 Positive Breast Cancer , Her2 Breast Cancer , Hormone Therapy , Basal Cell Carcinoma , Asal Cell Carcinoma Of The Skin , Skin Cancer , Alignant Skin Neoplasm , Europe , European , Oncological Medicine , Neoadjuvant , Triple Negative Breast Cancer , Biologic Thera ,